Recent attention shifted to platelet Btk as a potential therapeutic target in platelet-related thrombotic diseases [18,19,20,21,22,23], but clinically used Btk inhibitors affecting platelet functions may also cause bleeding events [22,24]. Here, BTK is linked to thrombotic disease.